Regulatory T Cell Immunotherapy for Type 1 Diabetes: A Step Closer to Success?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 26863486.
- Also identified by DOI 10.1016/j.cmet.2016.01.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Regulatory T cell (Treg) therapy has shown promises in experimental models of type 1 diabetes (T1D) and other autoimmune diseases. Now, Bluestone et al. (2015) report in a phase 1, dose-escalation study that ex vivo-expanded autologous polyclonal Treg therapy is safe and well tolerated in adult patients with recent-onset T1D.
Medical subject headings
- Diabetes Mellitus, Type 1
- T-Lymphocytes, Regulatory